{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.703","value":"-0.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"X-ray (n= 6, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.243","value":"-0.35"},{"groupId":"OG001","spread":"1.043","value":"-0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"DEXA (n = 14, 10)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"The summary of bone age and Dual-energy X-ray absorptiometry (DEXA) by cohort. Alteration of bone biochemical markers of hand and wrist X-Ray evaluation was observed in bone age standard deviation scores (SDS) and for bone mineral density for DEXA before and after treatment with nilotinib.","dispersionType":"Standard Deviation","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"},{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis","id":"OG001","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"MEAN","populationDescription":"Safety Set (SAF): All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Cycle 66","title":"Long Term Effect of Nilotinib on Bone Metabolism","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage of participants"}